This study evaluated 136 participants with retinoblastoma and demonstrated that MSK-ACCESS, a cfDNA and buffy coat DNA-matched clinical assay, can detect mosaic RB1 variants with VAFs as low as 1%. The gene discussed is RB1; the disease is retinoblastoma.